Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Scholar Rock, Inc.

Clinical trials sponsored by Scholar Rock, Inc., explained in plain language.

Scholar Rock, Inc. SRRK NASDAQ

A biopharmaceutical company developing therapies targeting growth factors for neuromuscular and other diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet finished but already full! 1 Completed 2

Early access to experimental SMA drug apitegromab offered before approval

Disease control NO_LONGER_AVAILABLE

This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed…

Sponsor: Scholar Rock, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:24 UTC